New drug duo enters human trials for Tough-to-Treat cancers
NCT ID NCT05689853
Summary
This early-stage study is testing the safety and initial effectiveness of combining two experimental drugs, AK119 and AK112, in adults with advanced solid tumors that have stopped responding to standard treatments. The trial will enroll about 87 participants to determine the right dose and see if the combination can shrink tumors. The goal is to control cancer growth and extend life, not to provide a cure that eliminates all treatment needs.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR, ADULT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking Union Medical College Hospital
RECRUITINGBeijing, Beijing Municipality, 100005, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.